Company / Interest Expense
Monopar Therapeutics Interest Expense History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$21.2K
FY2023
5-year range
$21.2K / $48.3K
FY2019-FY2023
Trend
-
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $7,232 to $21,239 over the past 6 years.
Based on SEC 10-K filings.
$21,239 in FY2023.
Increased from $7,232 to $21,239 over the past 6 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -15.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -15.1%, indicating a declining trend.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $21.2K | - |
| FY2019 | - | - |
| FY2018 | $48.3K | +567.2% |
| FY2017 | $7.2K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026